$9.66
6.27% today
Nasdaq, Nov 26, 04:49 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Target price 2024 - Analyst rating & recommendation

Ocular Therapeutix Inc Classifications & Recommendation:

Buy
100%

Ocular Therapeutix Inc Price Target

Target Price $18.22
Price $9.09
Potential
Number of Estimates 9
9 Analysts have issued a price target Ocular Therapeutix Inc 2025 . The average Ocular Therapeutix Inc target price is $18.22. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 9 Analysts recommend Ocular Therapeutix Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Ocular Therapeutix Inc stock has an average upside potential 2025 of . Most analysts recommend the Ocular Therapeutix Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 58.44 63.76
13.50% 9.10%
EBITDA Margin -135.87% -258.66%
8.61% 90.38%
Net Margin -273.41% -286.92%
2.32% 4.94%

8 Analysts have issued a sales forecast Ocular Therapeutix Inc 2024 . The average Ocular Therapeutix Inc sales estimate is

$63.8m
Unlock
. This is
3.77% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$66.1m 7.61%
Unlock
, the lowest is
$62.3m 1.40%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $58.4m 13.50%
2024
$63.8m 9.10%
Unlock
2025
$72.3m 13.35%
Unlock
2026
$85.0m 17.62%
Unlock
2027
$157m 84.36%
Unlock
2028
$469m 199.22%
Unlock

2 Analysts have issued an Ocular Therapeutix Inc EBITDA forecast 2024. The average Ocular Therapeutix Inc EBITDA estimate is

$-165m
Unlock
. This is
19.98% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-162m 18.20%
Unlock
, the lowest is
$-167m 21.75%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-79.4m 3.72%
2024
$-165m 107.71%
Unlock
2025
$-184m 11.76%
Unlock
2026
$-198m 7.29%
Unlock
2027
$-135m 31.96%
Unlock
2028
$13.3m 109.85%
Unlock

EBITDA Margin

2023 -135.87% 8.61%
2024
-258.66% 90.38%
Unlock
2025
-255.03% 1.40%
Unlock
2026
-232.63% 8.78%
Unlock
2027
-85.86% 63.09%
Unlock
2028
2.83% 103.30%
Unlock

8 Ocular Therapeutix Inc Analysts have issued a net profit forecast 2024. The average Ocular Therapeutix Inc net profit estimate is

$-183m
Unlock
. This is
11.53% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-147m 28.79%
Unlock
, the lowest is
$-196m 5.30%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-160m 10.87%
2024
$-183m 14.49%
Unlock
2025
$-166m 9.44%
Unlock
2026
$-167m 0.89%
Unlock
2027
$-149m 11.12%
Unlock
2028
$29.6m 119.90%
Unlock

Net Margin

2023 -273.41% 2.32%
2024
-286.92% 4.94%
Unlock
2025
-229.23% 20.11%
Unlock
2026
-196.64% 14.22%
Unlock
2027
-94.81% 51.78%
Unlock
2028
6.30% 106.64%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -1.02 -1.17
10.87% 14.71%
P/E negative
EV/Sales 16.89

8 Analysts have issued a Ocular Therapeutix Inc forecast for earnings per share. The average Ocular Therapeutix Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.17
Unlock
. This is
11.36% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.94 28.79%
Unlock
, the lowest is
$-1.25 5.30%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-1.02 10.87%
2024
$-1.17 14.71%
Unlock
2025
$-1.06 9.40%
Unlock
2026
$-1.07 0.94%
Unlock
2027
$-0.95 11.21%
Unlock
2028
$0.19 120.00%
Unlock

P/E ratio

Current -6.89 242.79%
2024
-7.78 12.92%
Unlock
2025
-8.60 10.54%
Unlock
2026
-8.52 0.93%
Unlock
2027
-9.58 12.44%
Unlock
2028
48.18 602.92%
Unlock

Based on analysts' sales estimates for 2024, the Ocular Therapeutix Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

16.89
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
22.41
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 17.53 571.65%
2024
16.89 3.64%
Unlock
2025
14.90 11.78%
Unlock
2026
12.67 14.98%
Unlock
2027
6.87 45.76%
Unlock
2028
2.30 66.58%
Unlock

P/S ratio

Current 23.26 654.68%
2024
22.41 3.64%
Unlock
2025
19.77 11.78%
Unlock
2026
16.81 14.98%
Unlock
2027
9.12 45.76%
Unlock
2028
3.05 66.58%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today